
    
      This prospective open multi-center non-interventional study assess the safety and
      effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac
      polymerized with house dust mite pediatric allergic patients in routine medical care.

      Patients receive a rush schedule administration every month for a year. They attend at least
      5 study visits to inform about the adverse reactions, the self reported symptoms and the
      medication intake.
    
  